Table 1 Demographics and clinical characteristics between the ICG and non-ICG groups
ICG (n = 28) | Non-ICG (n = 28) | P value | |
|---|---|---|---|
Age (yrs.) | 57.96±12.66 | 59.17±9.17 | 0.6874 |
Gender (male, %) | 19 (67.86%) | 20 (71.43%) | 0.7713 |
ASA-PS | >0.9999 | ||
II | 13 (46.43%) | 13 (46.43%) | - |
III | 15 (53.57%) | 15 (53.57%) | - |
BMI (kg/m2) | 22.25±2.32 | 22.86±2.73 | 0.3716 |
Tumor location | 0.2049 | ||
Upper third | 7 (25.00%) | 10 (35.71%) | - |
Middle third | 11 (39.29%) | 5 (17.86%) | - |
Lower third | 10 (35.71%) | 13 (46.43%) | - |
cT stage | 0.7744 | ||
cT1 | 17 (60.72%) | 19 (67.86%) | - |
cT2 | 8 (28.57%) | 5 (17.86%) | - |
cT3 | 3 (10.71%) | 3 (10.71%) | - |
cT4 | 0 | 1 (3.57%) | - |
cN stage | >0.9999 | ||
cN0 | 20 (71.43%) | 20 (71.43%) | - |
cN+ | 8 (28.57%) | 8 (28.57%) | - |
Clinical stage | 0.6862 | ||
I+II | 25 (89.29%) | 24 (85.71%) | - |
III+IV | 3 (10.71%) | 4 (14.29%) | - |
Histological type | 0.5920 | ||
Well/Moderate | 14 (50.00%) | 12 (42.86%) | - |
Poor/Undifferentiated | 14 (50.00%) | 16 (57.14%) | - |